Genta Inc. (GNTA.OB) Releases Positive Results of Regarding its Bone-Loss Treatment
Bone loss is associated with many different diseases, such as osteoporosis, metastasis in cancer, Parkinson’s disease, Paget’s disease and hypercalcemia. Regardless of its derivative, accelerated bone loss can hinder everyday tasks. Genta Inc. (OTCBB: GNTA) is a biopharmaceutical company with a diversified product portfolio focused on developing innovative products aimed at the treatment of cancer and diseases associated with accelerated bone loss. The company today announced its final results for its phase 1 clinical trial of G4544, a proprietary small molecule intended to treat diseases associated with accelerated bone loss. G4544 is a new tablet formulation using delivery technology developed…